Yes, Stelara is a biologic
Stelara (ustekinumab) is a fully human monoclonal antibody biologic drug. It targets interleukins 12 and 23 to treat conditions like psoriasis, Crohn's disease, and ulcerative colitis.[1]
How does Stelara work as a biologic?
Monoclonal antibodies like Stelara are lab-produced proteins that mimic the immune system's antibodies. Stelara binds specifically to IL-12 and IL-23 proteins, blocking their activity and reducing inflammation in autoimmune diseases.[1][2]
What sets biologics like Stelara apart from traditional drugs?
Unlike small-molecule drugs made via chemical synthesis, biologics derive from living cells, making them complex and harder to replicate. This leads to higher development costs and no generic equivalents—only biosimilars after patent expiry.[2]
When does Stelara's patent protection end?
Core U.S. patents for Stelara expire in 2023-2025, with some pediatric extensions to 2027. Multiple biosimilar challenges are underway, including from Samsung Bioepis and Alvotech.3
Common patient questions about Stelara
How is it administered?
Subcutaneous injections every 12 weeks after initial doses, or IV for Crohn's induction.[1]
What side effects do users report?
Infections, headache, fatigue, and rare risks like serious infections or cancer. Upper respiratory infections top the list.[1][2]
Stelara vs. other biologics for psoriasis or IBD
| Drug | Target | Conditions | Dosing Frequency |
|------|--------|------------|------------------|
| Stelara | IL-12/23 | Psoriasis, Crohn's, UC | Every 12 weeks |
| Humira (adalimumab) | TNF-alpha | Psoriasis, Crohn's, UC, RA | Every 1-2 weeks |
| Skyrizi (risankizumab) | IL-23 | Psoriasis, Crohn's | Every 12 weeks |
| Tremfya (guselkumab) | IL-23 | Psoriasis | Every 8 weeks |
Stelara shows high efficacy in head-to-head trials but faces competition from more selective IL-23 inhibitors.[2]
Biosimilars on the horizon for Stelara
FDA approved Pyzchiva (ustekinumab-aauv) as the first Stelara biosimilar in 2024, with launch possible post-patent settlement in 2025. Others like Selarsdi and Yesafili follow.3
[1]: https://www.stelara.com/
[2]: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/ustekinumab-stelara-information